MAPRE2 and melanoma: However, a recent report showed that existing RAF inhibitors cannot suppress RAF1-fusion-driven signaling pathways, and our study also showed that a melanoma patient harboring MAPRE2-RAF1 fusion did not respond to vemurafenib [32].